NCT05743634View on ClinicalTrials.gov

A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

February 13, 2023

Study Completion Date

February 13, 2023

Conditions
Moderate to Severe Glabellar Lines
Interventions
BIOLOGICAL

YY001

Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

BIOLOGICAL

OnabotulinumtoxinA

Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

BIOLOGICAL

Placebo

Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

Trial Locations (6)

Unknown

Peking Union Medical College Hospital, Beijing

The First affiliated Hospital of Chongqing Medical University, Chongqing

Nanfang Hospital,Southern Medical University, Guangzhou

Shanghai Ninth People's Hospital,Shanghai JiaoTong University school of Medicine, Shanghai

West China Hospital,Sichuan University, Chengdu

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
lead

Chongqing Claruvis Pharmaceutical Co., Ltd.

INDUSTRY